PET-CT Identifies High-Risk Smoldering Multiple Myeloma Patients Needing Treatment

Overview

This study demonstrates that PET-CT imaging at diagnosis of smoldering multiple myeloma (SMM) effectively identifies patients at high risk of progression to active multiple myeloma (MM) within 2 years. Patients with positive PET-CT findings, especially those with osteolytic lesions, had significantly shorter time to progression compared to those with negative PET-CT scans.

Background

Smoldering multiple myeloma (SMM) is an asymptomatic intermediate stage with about a 50% risk of progression to active MM within 5 years. Current management involves observation until symptoms develop, but early treatment of high-risk patients may improve outcomes. Biomarkers and imaging modalities are being investigated to better stratify risk. While MRI has shown prognostic value, the role of PET-CT in guiding treatment decisions in SMM remains less defined.

Data Highlights

Key Findings

• Among 188 SMM patients undergoing PET-CT, 74 had positive scans; 49 were diagnosed as active MM, with 24% upstaged solely based on PET-CT findings.
• In patients observed without therapy, those with positive PET-CT had a 75% progression rate to MM within 2 years versus 30% with negative PET-CT (P=0.0008).
• Presence of osteolytic lesions on PET-CT was associated with an 87% 2-year progression rate, significantly higher than those without osteolysis (P=0.004).
• In patients scanned within 90 days of SMM diagnosis, positive PET-CT predicted an 82% 2-year progression rate compared to 28% with negative scans (P=0.0006).
• Median overall survival was not reached, but 5-year survival was lower in patients with positive PET-CT (61%) versus negative PET-CT (82%).

Clinical Implications

PET-CT imaging at SMM diagnosis provides valuable prognostic information and can identify patients at high risk of progression who may benefit from early therapeutic intervention. Detection of osteolytic lesions on PET-CT should prompt closer monitoring or consideration of treatment initiation. Incorporating PET-CT into the diagnostic workup may improve risk stratification beyond traditional laboratory markers.

Conclusion

PET-CT is a useful tool for identifying smoldering multiple myeloma patients at high risk of progression to active disease, particularly when osteolytic lesions are present. This imaging modality can guide clinical decision-making regarding early treatment versus observation.

References

1. Rajkumar SV et al. 2014 -- International Myeloma Working Group updated criteria for diagnosis of multiple myeloma
2. Hillengass J et al. 2010 -- MRI focal lesions predict progression in smoldering multiple myeloma
3. Kumar S et al. 2015 -- Role of PET-CT in smoldering multiple myeloma